ID30064A - Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion - Google Patents

Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Info

Publication number
ID30064A
ID30064A IDW00200101331A ID20011331A ID30064A ID 30064 A ID30064 A ID 30064A ID W00200101331 A IDW00200101331 A ID W00200101331A ID 20011331 A ID20011331 A ID 20011331A ID 30064 A ID30064 A ID 30064A
Authority
ID
Indonesia
Prior art keywords
crystal
methyl
tiazolidinedion
fluorobenzil
oksi
Prior art date
Application number
IDW00200101331A
Other languages
English (en)
Inventor
Takayuki Oe
Hiroaki Ueno
Akira Maruyama
Katsuhiko Masuda
Original Assignee
Mitsibishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsibishi Chemical Corp filed Critical Mitsibishi Chemical Corp
Publication of ID30064A publication Critical patent/ID30064A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cosmetics (AREA)
IDW00200101331A 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion ID30064A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
ID30064A true ID30064A (id) 2001-11-01

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101331A ID30064A (id) 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Country Status (23)

Country Link
US (3) US6541493B1 (id)
EP (1) EP1131310B1 (id)
JP (1) JP3784001B2 (id)
KR (1) KR100652326B1 (id)
CN (1) CN1326449A (id)
AT (1) ATE315552T1 (id)
AU (1) AU1185100A (id)
BR (1) BR9916795A (id)
CA (1) CA2351727C (id)
CZ (1) CZ20011763A3 (id)
DE (1) DE69929476T2 (id)
ES (1) ES2257104T3 (id)
HU (1) HUP0104139A3 (id)
ID (1) ID30064A (id)
IL (1) IL143177A0 (id)
NO (1) NO20012444L (id)
NZ (1) NZ512429A (id)
PL (1) PL348502A1 (id)
PT (1) PT1131310E (id)
TR (4) TR200202103T2 (id)
TW (2) TWI250156B (id)
WO (1) WO2000031055A1 (id)
ZA (1) ZA200104081B (id)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID30064A (id) * 1998-11-20 2001-11-01 Mitsibishi Chemical Corp Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion
CN1423639A (zh) * 1999-11-19 2003-06-11 奥索-麦克尼尔药品公司 5－[[6－[(2－氟苯基)甲氧基]－2－萘基]甲基]－2,4－噻唑烷二酮的多种固态形式
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
PL2303267T3 (pl) * 2008-02-04 2013-11-29 Pfizer Ltd Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
ID30064A (id) * 1998-11-20 2001-11-01 Mitsibishi Chemical Corp Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Also Published As

Publication number Publication date
IL143177A0 (en) 2002-04-21
JP2002530392A (ja) 2002-09-17
ZA200104081B (en) 2002-05-20
TR200202103T2 (tr) 2002-11-21
EP1131310A1 (en) 2001-09-12
PT1131310E (pt) 2006-05-31
TWI272944B (en) 2007-02-11
DE69929476D1 (de) 2006-04-06
AU1185100A (en) 2000-06-13
ES2257104T3 (es) 2006-07-16
NO20012444L (no) 2001-07-18
NZ512429A (en) 2003-11-28
JP3784001B2 (ja) 2006-06-07
KR100652326B1 (ko) 2006-11-29
CN1326449A (zh) 2001-12-12
PL348502A1 (en) 2002-05-20
TR200202110T2 (tr) 2002-10-21
BR9916795A (pt) 2002-04-09
TR200202109T2 (tr) 2002-11-21
US20030158241A1 (en) 2003-08-21
US6541493B1 (en) 2003-04-01
NO20012444D0 (no) 2001-05-18
KR20010101033A (ko) 2001-11-14
EP1131310B1 (en) 2006-01-11
DE69929476T2 (de) 2006-09-14
US20060149075A1 (en) 2006-07-06
TW200613291A (en) 2006-05-01
CA2351727A1 (en) 2000-06-02
CZ20011763A3 (cs) 2001-10-17
ATE315552T1 (de) 2006-02-15
TR200101901T2 (tr) 2002-04-22
TWI250156B (en) 2006-03-01
WO2000031055A1 (en) 2000-06-02
CA2351727C (en) 2008-09-23
HUP0104139A3 (en) 2003-12-29
HUP0104139A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
AU782631C (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
HUP9901960A3 (en) Pharmaceutical compositions containing crystalline ziprasidone and process for preparation of the crystals
BG103268A (en) Propionic acid derivatives and their application
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AR031069A1 (es) Cristal de un compuesto benzimidazol, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
IL126674A (en) Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
FI911646A7 (fi) DTPA-monoamideja, näitä yhdisteitä sisältäviä farmaseuttisia aineita, niiden käyttö ja menetelmä niiden valmistamiseksi
EA200000656A1 (ru) Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение
EA200000654A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]-тиазолидин-2,4-диона в качестве фармацевтического препарата
IT1158025B (it) Derivati di 3-ammino pregn-5-ene e loro sali, procedimento per la loro preparazione, per l'applicazione come medicamenti e composizioni che li contengono
FI902673A7 (fi) Anti-inflammatoorisia ja analgeettisia yhdisteitä, niitä sisältäviä se oksia ja menetelmiä niiden valmistamiseksi sekä niiden käyttö
BR9813604A (pt) Hidrato de sal de ácido maleico 5-[4-[2- (n-metil-n-(2-piridil) amino) etóxi]benzil]tiazolidina-2,4-diona
PT1131310E (pt) Cristais de 5-[{6-(2-fluorobenzil)oxi-2-naftil}metil]-2,4-tiazolidinadiona
NO996467L (no) FremgangsmÕte for fremstilling av tiazofurin og andre C- nukleosider
ZA845723B (en) Compounds for lowering lipid levels
FI803704A7 (fi) Heterosyklinen yhdiste ja sen synteesi, sitä sisältävät farmaseuttiset koostumukset ja yhdisteiden ja koostumukoostumusten käyttö lääketieteessä.
IL77051A (en) Crystalline form of the monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide and pharmaceutical compositions containing it
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
IL67564A0 (en) (1,2)-fused 1,4-benzodiazepine compounds,their preparation and pharmaceutical compositions containing them
DK31385D0 (da) Benzopyranderivater, kompositioner indeholdende disse forbindelser ogfremgangsmaade til forbindelsernes fremstilling
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
JPS57206683A (en) Pyrimidone salt, manufacture and medicinal composition containing same
NO970477D0 (no) Inhibisjon av leukotrien biosyntese med ureaderivater
JPS57140785A (en) Benzothiazine derivative, its preparation, and pharmaceutical composition containing the same